Introduction
The initial response to remission induction therapy is one of the most important prognostic factors in acute lymphoblastic leukemia (ALL). Patients who respond slowly have a high risk of relapse, 1, 2 while those who fail to attain a complete remission within 4 to 6 weeks of treatment have a particularly dismal prognosis. 3 Complete remission is currently defined as restoration of normal hematopoiesis with a blast cell fraction of less than 5% by light microscopic examination of the bone marrow. This relatively liberal definition reflects the difficulty of identifying leukemic lymphoblasts in regenerating marrow by morphologic criteria alone. Thus, patients with nearly 5% leukemic blast cells in their marrow specimens can harbor as many as 10 10 leukemic cells, and their treatment may not differ from that of patients with much larger reductions in the leukemic cell burden. 4 Conversely, normal hematopoietic progenitors ('hematogones'), which may represent 5% or more of the cells in regenerating marrow, can be erroneously interpreted as a sign of residual leukemia.
With use of flow cytometry (to detect aberrant immunophenotypes) or polymerase chain reaction (PCR) analysis (to detect rearrangements of antigen receptor genes), it is now possible to search for minimal residual disease (MRD) during clinical remission in approximately 90% of patients. 5, 6 Either method is at least 100-fold more sensitive than morphologic examination of marrow specimens and consistently identifies one leukemic cell among 10 4 or more normal bone marrow cells. Recent demonstration of the independent prognostic significance of MRD levels in remission bone marrow samples using these methods [7] [8] [9] provided the impetus to redefine complete remission in patients with ALL. 10 However, several critical issues must be addressed before MRD determinations can be routinely considered in clinical decision making.
Universal monitoring of MRD
A prerequisite for applying MRD measurements in clinical trials is that data should be available for all patients. This obstacle could be overcome by increasing the numbers of leukemic cell markers and target genes amenable to flow cytometric and PCR analyses, respectively. An alternative strategy would be to apply these methods in tandem. Indeed, we have found good concordance between results obtained with the two techniques. 11 Tandem application of flow cytometry and PCR testing would not only allow one to study marrow samples from all patients, but may also reduce the likelihood of false-negative results due to changes in the predominant immunophenotypes or gene rearrangements during the disease course.
MRD levels of clinical importance
The number of residual leukemic cells varies widely among patients, raising the issue of which levels are in fact predictive of clinical outcome. In one study, an MRD level of 0.5 to 5 × 10 −5 cells during remission did not correlate with subsequent relapse, 12 suggesting that the residual cells were either preleukemic or in a nonproliferative state, or perhaps were eventually eradicated by the patient's immune system.
Although not yet confirmed by others, this finding suggests that MRD levels of 10 −5 or lower are not clinically relevant. By contrast, levels of 10 −4 or greater correlated with an increased relapse hazard in three recent studies. [7] [8] [9] Patients without detectable MRD or with a level below 10 −4 had a 3-year cumulative risk of relapse of less than 10%, compared with 56% to 78% for those with 10 −2 or more residual blasts (Table 1) . Only two of our nine patients with high MRD levels at the end of induction are alive and in remission at 2.5 and 4.5 years post-diagnosis (the second child underwent hematopoietic stem cell transplantation in first remission). Patients in this category appear to fare as poorly as induction failures identified by traditional criteria and clearly should be managed as very high-risk cases.
The clinical importance of MRD levels between 10 −4 and . Thus, the immunologic remission rate was 75%. Another 12% of the patients required from 7 to 22 weeks of therapy to attain such a remission, with all remaining patients requiring more than 22 weeks. 
10
−2 is less certain. Possibly, a level of 10 −3 could be used to discriminate between patients with lower and higher risks of relapse. We and others observed that patients with MRD at or above the 10 −3 level following consolidation therapy (1 to 3 months post-remission) have an especially high rate of relapse, 7-9 almost comparable to that of patients classified as induction failures. In any case, accurate quantification of MRD levels appears to be a critical component of sound clinical management. Flow cytometry is well suited for this purpose because it allows direct enumeration of viable leukemic cells and normal cells. 6 The task is more difficult with PCR analysis, which relies on the measurement of a PCR product rather than cell counting; 4 however, 'real-time' PCR technology may substantially improve the utility of this method. 13 
Sequential monitoring of MRD
Until recently, very little was known about the kinetics of leukemic cell clearance and its clinical significance. A European multicenter study found that the outcome of therapy correlates well with the rapidity of leukemia reduction. 8 Patients without detectable MRD at the end of the induction phase fared better than those with an MRD level р10 −4 at week 7 postremission, who in turn had a better outcome than patients with persistently higher levels of MRD.
In an ongoing prospective study, we have noted several discrete patterns of leukemic cell clearance that may have clinical relevance (Figure 1 ).
14 Almost half of our patients lacked measurable disease by flow cytometric analysis after only 2 weeks of remission induction therapy. MRD was detected in 25% of the patients upon completion of the induction phase (week 6), in 13% during week 14 of continuation treatment, and 4% during week 32. Virtually all of the patients with MRD at week 32 have relapsed, while those with MRD at week 14 but not week 32 have had a relatively low relapse hazard (Ϸ14% with 3 years of follow-up). It is still uncertain whether the rapid disappearance of MRD during the first 2 weeks of remission induction confers a particularly favorable prognosis, allowing treatment reduction.
Recommendations
Now that cure rates in childhood ALL are approaching 80%, 10 we should begin to apply immunologic or molecular definitions of complete remission in risk assessment. The findings summarized here indicate that an MRD level of less than 10
leukemic cells upon completion of induction therapy predicts a very favorable prognosis. Sequential monitoring of MRD may not be necessary for these patients. In our experience, only two of 123 such patients had detectable MRD before overt relapse. 14 The value of MRD at the end of therapy is questionable because a negative result would not preclude subsequent relapse. 7, 8 Hence, the disappearance of MRD should not be used as a reason for elective cessation of therapy.
Patients with 10 −2 or more leukemic cells during any phase of remission should be regarded as having a very high risk of relapse. Further studies are needed to define the significance of intermediate MRD levels (Ͼ10 −4 but Ͻ10 −2 ) during early remission.
In theory, more rapid and complete clearance of leukemic blast cells with treatment could forestall the emergence of drug-resistant subclones, resulting in a more favorable clinical outcome. Intensification of early postremission therapy improves the clinical outcome in patients with slow responses to remission induction therapy (more than 25% bone marrow blasts on day 7), 15 but randomized trials are needed to ascertain whether similar therapy would benefit patients with highrisk ALL defined by MRD assays. Investigators should continue to search for novel leukemic cell markers with high sensitivity and specificity. To this end, we have identified several useful new markers using cDNA microarrays, enabling us to apply flow cytometric MRD detection methods in over 90% of ALL cases. 16 Finally, an immunologic or molecular definition of complete remission could speed the development of optimal risk-directed therapy for children with ALL, boosting cure rates closer to 100%.
